News
15h
Medical Device Network on MSNBoston Scientific reports outcomes from Farapulse and Farapoint trialSubjects in the study were monitored using the LUX-Dx insertable cardiac monitor system to detect arrhythmia recurrence.
The upper pulmonary veins (PVs) are responsible for the majority of atrial fibrillation (AF) triggering foci, whereas the inferior PVs are more difficult to ablate and prone to postablation ostial ...
PFA is a newer Afib ablation modality touted as reducing the risk of damaging nearby collateral structures, compared with ...
Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of ...
Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, today announced the initiation of the ...
Omny-IRE data demonstrated the investigational OMNYPULSETM Platform achieved 100% acute success and 84.5% pulmonary vein isolation (PVI) durabilit ...
These foci are commonly in the superior pulmonary veins; this is an important factor in the electrophysiologic approach to atrial fibrillation, known as pulmonary vein isolation. Less commonly ...
Kardium today announced one-year clinical trial results for its Globe PF pulsed field ablation (PFA) system for treating AFib ...
"Second, PFA may yield more durable lesions, thereby reducing pulmonary-vein reconnections ... growing body of evidence supporting the use of PFA for the treatment of atrial fibrillation." "It shows ...
One of AI’s most immediate impacts is in screening and identifying patients who may have asymptomatic or paroxysmal AF, those ...
Boston Scientific (BSX) announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results